Last reviewed 2026-05-26 · How we verify

XS005 Sorafenib Capsule A - Period 2

Xspray Pharma AB · Phase 1 active Small molecule ✓ Verified May 2026

XS005 Sorafenib Capsule A - Period 2 is a Small molecule drug developed by Xspray Pharma AB. It is currently in Phase 1 development. Also known as: Regimen B, Regimen C.

XS005 Sorafenib Capsule A is a small molecule drug used in a clinical study to evaluate its pharmacokinetic parameters and relative bioavailability in healthy male subjects. The study, NCT05967377, compares the pharmacokinetics of XS005 Sorafenib Capsule A to Sorafenib and XS005 Sorafenib Tablet A.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	XS005 Sorafenib Capsule A - Period 2
Also known as	Regimen B, Regimen C
Sponsor	Xspray Pharma AB
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Evaluating the Pharmacokinetic Parameters and Relative Bioavailability of Sorafenib (XS005) in Healthy Male Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

XS005 Sorafenib Capsule A - Period 2 CI brief — competitive landscape report
XS005 Sorafenib Capsule A - Period 2 updates RSS · CI watch RSS
Xspray Pharma AB portfolio CI

Frequently asked questions about XS005 Sorafenib Capsule A - Period 2

What is XS005 Sorafenib Capsule A - Period 2?

XS005 Sorafenib Capsule A - Period 2 is a Small molecule drug developed by Xspray Pharma AB.

Who makes XS005 Sorafenib Capsule A - Period 2?

XS005 Sorafenib Capsule A - Period 2 is developed by Xspray Pharma AB (see full Xspray Pharma AB pipeline at /company/xspray-pharma-ab).

Is XS005 Sorafenib Capsule A - Period 2 also known as anything else?

XS005 Sorafenib Capsule A - Period 2 is also known as Regimen B, Regimen C.

What development phase is XS005 Sorafenib Capsule A - Period 2 in?

XS005 Sorafenib Capsule A - Period 2 is in Phase 1.

Manufacturer: Xspray Pharma AB — full pipeline
Also known as: Regimen B, Regimen C

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing